Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients

Strahlentherapie und Onkologie

Volumn 176, Issue 9, 2000, Pages 416-421

  Dunst, Jürgen ^b   Semlin, Susanne ^b   Pigorsch, Steffi ^b   Müller, Arndt Christian ^b   Reese, Thomas ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NONE

Author keywords

Acute toxicity; Amifostine; Radioprotection; Radiotherapy; Rectal cancer

Indexed keywords

AMIFOSTINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; FLUOROURACIL;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; HYPOTENSION; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTUM CANCER; TREATMENT OUTCOME;

EID: 0033817226     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00002350     Document Type: Article

References (16)

1. Cytoprotection with amifostine in radiotherapy or radiochemotherapy of head and neck tumors
2. Randomized phase III trial of radiation ± amifostine in patients with advanced stage lung cancer
3. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer
4. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
5. The sulfhydryl containing compounds WR-2721 and gluthathione as radio- and chemoprotective agents. A review, indications for use and prospects
6. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721
7. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy
8. Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer
9. Supportive use of amifostine in patients with haed and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
10. Randomized phase III trial of radiation ± amifostine in patients with head and neck cancer
11. Amifostine - A radioprotector in locally advanced head and neck tumors
12. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: Results of a phase II trial
13. Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study
14. A new administration schedule for amifostine as a radioprotector in cancer therapy
15. Radiotherapeutic studies with amifostine
16. Radioprotective effects of amifostine